
CLAIMS

1. A compound of Formula (I):



(I)

or a pharmaceutically acceptable prodrug, solvate, enantiomer, stereoisomer, tautomer, or salt thereof, wherein:

A is C_{3-10} cycloalkyl, 3- to 10-membered heterocyclyl comprising 1-4 heteroatoms selected from N, O, and S, C_{6-10} aryl, or 5- to 10-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, wherein the cycloalkyl or heterocyclyl is optionally substituted with oxo;

each R_x and R_y is independently H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, halogen, -CN, -OH, or $-NH_2$;

each R_1 and R_4 is independently H, C_{1-6} alkyl, C_{2-6} alkenyl, or C_{2-6} alkynyl;

each R_2 and R_3 is independently H, C_{2-6} alkenyl, C_{2-6} alkynyl, -O-C_{1-6} alkyl, -O-C_{2-6} alkenyl, -O-C_{2-6} alkynyl, $-C(O)R_{11}$, $-C(O)OR_{11}$, $-C(O)N(R_{11})_2$, $-C(O)NR_{11}$-$S(O)_2R_{11}$, $-C(O)NR_{11}$-$S(O)_2$-OR_{11}, or $-C(O)NR_{11}$-$S(O)_2$-$N(R_{11})_2$, wherein either R_2 or R_3 is not H;

each R_5 and R_6 is independently H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, 3- to 13-membered heterocyclyl comprising 1-4 heteroatoms selected from N, O, and S, C_{6-10} aryl, 5- to 13-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, or -$C(O)R_7$, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more R_7, or

R_5 and R_6 together with the atoms to which they are attached form a 4- to 10-membered heterocyclyl comprising 1-4 heteroatoms selected from N, O, and S, or 5- to 10-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, wherein the heterocyclyl or heteroaryl is optionally substituted with one or more R_7;

each R_7 is independently oxo, halogen, -OH, $-NH_2$, -CN, $-C(O)R_{10}$, $-C(O)OR_{10}$, $-C(O)N(R_{10})_2$, C_{1-3} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, $-NH(C_{1-6}$ alkyl), $-N(C_{1-6}$ alkyl$)_2$, $-O-(CH_2)_t-R_8$, $-NH-(CH_2)_t-R_8$, C_{3-10} cycloalkyl, 3- to 10-membered heterocyclyl comprising 1-4 heteroatoms selected from N, O, and S, C_{6-10} aryl, or 5- to 10-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more R_{10};

R_8 is -OH, C_{1-6} alkoxy, C_{1-6} alkoxy-OH, $-NH_2$, $-NH(C_{1-6}$ alkyl), $-N(C_{1-6}$ alkyl$)_2$, -SH, $-S(C_{1-6}$ alkyl), C_{3-10} cycloalkyl, 3- to 10-membered heterocyclyl comprising 1-4 heteroatoms selected from N, O, and S, C_{6-10} aryl, or 5- to 10-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, wherein the alkoxy, alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted by one or more R_9;

each R_9 is independently $-(CH_2)_u-$(5- to 10-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S) or $-(CH_2)_u-(C_{6-10}$ aryl), wherein the heteroaryl or aryl is optionally substituted with one or more halogen, -CN, -OH, or $-NH_2$;

each R_{10} is independently halogen, -OH, $-NH_2$, -CN, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{3-10} cycloalkyl, 3- to 10-membered heterocyclyl comprising 1-4 heteroatoms selected from N, O, and S, C_{6-10} aryl, or 5- to 10-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S;



each R_{11} is independently H, C_{1-6} alkyl, C_{2-6} alkenyl, or C_{2-6} alkynyl, wherein the alkyl, alkenyl, or alkynyl is optionally substituted with one or more C_{3-10} cycloalkyl, 3- to 10-membered heterocyclyl comprising 1-4 heteroatoms selected from N, O, and S, C_{6-10} aryl, or 5- to 10-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, wherein the cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more C_{3-10} cycloalkyl, 3- to 10-membered heterocyclyl comprising 1-4 heteroatoms selected from N, O, and S, C_{6-10} aryl, 5- to 10-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, oxo, halogen, -CN, -OH, or $-NH_2$, or

two R_{11} together with the atom to which they are attached form a 4- to 10-membered heterocyclyl comprising 1-4 heteroatoms selected from N, O, and S, or 5- to 10-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, wherein the heterocyclyl or heteroaryl is optionally substituted with one or more C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, halogen, -CN, -OH, or $-NH_2$;


each n, m, and p is independently 0 or 1;

t is 1, 2, or 3; and

u is 0, 1, 2, or 3,




wherein R_5 and R_6 together with the atoms to which they are attached form a heterocyclyl or heteroaryl, A is not phenyl, , or .

2. A compound of Formula (I):



(I)

or a pharmaceutically acceptable prodrug, solvate, enantiomer, stereoisomer, tautomer, or salt thereof, wherein:

A is , , or ;

each R_x and R_y is independently H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, halogen, -CN, -OH, or $-NH_2$;

each R_1 and R_4 is independently H, C_{1-6} alkyl, C_{2-6} alkenyl, or C_{2-6} alkynyl;

each R_2 and R_3 is independently H, C_{2-6} alkenyl, C_{2-6} alkynyl, -O-C_{1-6} alkyl, -O-C_{2-6} alkenyl, -O-C_{2-6} alkynyl, $-C(O)R_{11}$, $-C(O)OR_{11}$, $-C(O)N(R_{11})_2$, $-C(O)NR_{11}-S(O)_2R_{11}$, $-C(O)NR_{11}-S(O)_2-OR_{11}$, or $-C(O)NR_{11}-S(O)_2-N(R_{11})_2$, wherein either R_2 or R_3 is not H;

each R_5 and R_6 is independently H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, 3- to 13-membered heterocyclyl comprising 1-4 heteroatoms selected from N, O, and S, C_{6-10} aryl, 5- to 13-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, or -

$C(O)R_7$, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more R_7, or

R_5 and R_6 together with the atoms to which they are attached form a 4- to 10-membered heterocyclyl comprising 1-4 heteroatoms selected from N, O, and S, or 5- to 10-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, wherein the heterocyclyl or heteroaryl is optionally substituted with one or more R_7;

each R_7 is independently oxo, halogen, -OH, $-NH_2$, -CN, $-C(O)R_{10}$, $-C(O)OR_{10}$, $-C(O)N(R_{10})_2$, C_{1-3} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, $-NH(C_{1-6}$ alkyl), $-N(C_{1-6}$ alkyl$)_2$, $-O-(CH_2)_t-R_8$, $-NH-(CH_2)_t-R_8$, C_{3-10} cycloalkyl, 3- to 10-membered heterocyclyl comprising 1-4 heteroatoms selected from N, O, and S, C_{6-10} aryl, or 5- to 10-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more R_{10};

R_8 is -OH, C_{1-6} alkoxy, C_{1-6} alkoxy-OH, $-NH_2$, $-NH(C_{1-6}$ alkyl), $-N(C_{1-6}$ alkyl$)_2$, -SH, $-S(C_{1-6}$ alkyl), C_{3-10} cycloalkyl, 3- to 10-membered heterocyclyl comprising 1-4 heteroatoms selected from N, O, and S, C_{6-10} aryl, or 5- to 10-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, wherein the alkoxy, alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted by one or more R_9;

each R_9 is independently $-(CH_2)_u-$(5- to 10-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S) or $-(CH_2)_u-(C_{6-10}$ aryl), wherein the heteroaryl or aryl is optionally substituted with one or more halogen, -CN, -OH, or $-NH_2$;

each R_{10} is independently halogen, -OH, $-NH_2$, -CN, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{3-10} cycloalkyl, 3- to 10-membered heterocyclyl comprising 1-4 heteroatoms selected from N, O, and S, C_{6-10} aryl, or 5- to 10-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S;

each R_{11} is independently H, C_{1-6} alkyl, C_{2-6} alkenyl, or C_{2-6} alkynyl, wherein the alkyl, alkenyl, or alkynyl is optionally substituted with one or more C_{3-10} cycloalkyl, 3- to 10-membered heterocyclyl comprising 1-4 heteroatoms selected from N, O, and S, C_{6-10} aryl, or 5- to 10-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, wherein the cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more C_{3-10} cycloalkyl, 3- to 10-membered heterocyclyl comprising 1-4 heteroatoms selected from N, O, and


S, C_{6-10} aryl, 5- to 10-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, oxo, halogen, -CN, -OH, or $-NH_2$, or

two R_{11} together with the atom to which they are attached form a 4- to 10-membered heterocyclyl comprising 1-4 heteroatoms selected from N, O, and S, or 5- to 10-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, wherein the heterocyclyl or heteroaryl is optionally substituted with one or more C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, halogen, -CN, -OH, or $-NH_2$;

each n, m, and p is independently 0 or 1;


t is 1, 2, or 3; and

u is 0, 1, 2, or 3,

wherein R_5 and R_6 together with the atoms to which they are attached form a heterocyclyl, A is 

.

3. A compound of Formula (II):



(II)

or a pharmaceutically acceptable prodrug, solvate, enantiomer, stereoisomer, tautomer, or salt thereof, wherein:

each R_x and R_y is independently H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, halogen, -CN, -OH, or $-NH_2$;

each R_1 and R_4 is independently H, C_{1-6} alkyl, C_{2-6} alkenyl, or C_{2-6} alkynyl;

each R_2 and R_3 is independently H, C_{2-6} alkenyl, C_{2-6} alkynyl, -C(O)R_{11}, -C(O)OR_{11}, -C(O)N(R_{11})$_2$, -C(O)NR_{11}-S(O)$_2$$R_{11}$, -C(O)N$R_{11}$-S(O)$_2$-O$R_{11}$, or -C(O)N$R_{11}$-S(O)$_2$-N($R_{11}$)$_2$, wherein either R_2 or R_3 is not H;

each R_5 and R_6 is independently H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, 3- to 13-membered heterocyclyl comprising 1-4 heteroatoms selected from N, O, and S, C_{6-10} aryl, 5- to 13-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, or -C(O)R_7, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more R_7, or

R_5 and R_6 together with the atoms to which they are attached form a 4- to 10-membered heterocyclyl comprising 1-4 heteroatoms selected from N, O, and S, or 5- to 10-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, wherein the heterocyclyl or heteroaryl is optionally substituted with one or more R_7;

each R_7 is independently oxo, halogen, -OH, -NH_2, -CN, -C(O)R_{10}, -C(O)OR_{10}, -C(O)N(R_{10})$_2$, C_{1-3} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, -NH(C_{1-6} alkyl), -N(C_{1-6} alkyl)$_2$, -O-(CH_2)$_t$-R_8, -NH-(CH_2)$_t$-R_8, C_{3-10} cycloalkyl, 3- to 10-membered heterocyclyl comprising 1-4 heteroatoms selected from N, O, and S, C_{6-10} aryl, or 5- to 10-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more R_{10};

R_8 is -OH, C_{1-6} alkoxy, C_{1-6} alkoxy-OH, -NH_2, -NH(C_{1-6} alkyl), -N(C_{1-6} alkyl)$_2$, -SH, -S(C_{1-6} alkyl), C_{3-10} cycloalkyl, 3- to 10-membered heterocyclyl comprising 1-4 heteroatoms selected from N, O, and S, C_{6-10} aryl, or 5- to 10-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, wherein the alkoxy, alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted by one or more R_9;

each R_9 is independently -(CH_2)$_u$-(5- to 10-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S) or -(CH_2)$_u$-(C_{6-10} aryl), wherein the heteroaryl or aryl is optionally substituted with one or more halogen, -CN, -OH, or -NH_2;

each R_{10} is independently halogen, -OH, -NH_2, -CN, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{3-10} cycloalkyl, 3- to 10-membered heterocyclyl comprising 1-4 heteroatoms selected from N, O, and S, C_{6-10} aryl, or 5- to 10-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S;

each R_{11} is independently H, C_{1-6} alkyl, C_{2-6} alkenyl, or C_{2-6} alkynyl, wherein the alkyl, alkenyl, or alkynyl is optionally substituted with one or more C_{3-10} cycloalkyl, 3- to 10-membered heterocyclyl comprising 1-4 heteroatoms selected from N, O, and S, C_{6-10} aryl, or 5- to 10-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, wherein the cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more C_{3-10} cycloalkyl, 3- to 10-membered heterocyclyl comprising 1-4 heteroatoms selected from N, O, and S, C_{6-10} aryl, 5- to 10-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, oxo, halogen, -CN, -OH, or $-NH_2$, or

two R_{11} together with the atom to which they are attached form a 4- to 10-membered heterocyclyl comprising 1-4 heteroatoms selected from N, O, and S, or 5- to 10-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, wherein the heterocyclyl or heteroaryl is optionally substituted with one or more C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, halogen, -CN, -OH, or $-NH_2$;

each n, m, and p is independently 0 or 1;

t is 1, 2, or 3; and

u is 0, 1, 2, or 3.

4. The compound of any one of preceding claims, wherein each R_x and R_y is independently H, C_{1-6} alkyl, or -OH.

5. The compound of any one of preceding claims, each R_1 and R_4 is independently H or C_{1-6} alkyl.

6. The compound of claim 1 or 2, each R_2 and R_3 is independently -O-C_{1-6} alkyl, $-C(O)R_{11}$, $-C(O)OR_{11}$, $-C(O)N(R_{11})_2$, or $-C(O)NR_{11}$-$S(O)_2R_{11}$.

7. The compound of any one of preceding claims, each R_5 and R_6 is independently H, C_{1-6} alkyl, C_{3-10} cycloalkyl, 3- to 13-membered heterocyclyl comprising 1-4 heteroatoms selected from N, O, and S, C_{6-10} aryl, 5- to 13-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, or $-C(O)R_7$, wherein the alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more R_7.

8. The compound of any one of preceding claims, each R_5 and R_6 is independently H, C_{1-6} alkyl, C_{3-10} cycloalkyl, 3- to 13-membered heterocyclyl comprising 1-4 heteroatoms selected from N, O, and S, C_{6-10} aryl, or 5- to 13-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, wherein the alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more R_7.

9. The compound of any one of preceding claims, each R_5 and R_6 is independently H, C_{1-6} alkyl, C_{3-10} cycloalkyl, 3- to 13-membered heterocyclyl comprising 1-4 heteroatoms selected from N, O, and S, C_{6-10} aryl, or 5- to 13-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, wherein the alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is substituted with one or more R_7.

10. The compound of any one of preceding claims, R_5 and R_6 together with the atoms to which they are attached form a 4- to 10-membered heterocyclyl comprising 1-4 heteroatoms selected from N, O, and S, or 5- to 10-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, wherein the heterocyclyl or heteroaryl is substituted with one or more R_7.

11. The compound of any one of preceding claims, each R_7 is independently oxo, halogen, -OH, $-NH_2$, -CN, $-C(O)R_{10}$, C_{1-3} alkyl, C_{2-6} alkynyl, $-O-(CH_2)_t-R_8$, C_{6-10} aryl, or 5- to 10-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, wherein the alkyl, alkynyl, aryl, or heteroaryl is optionally substituted with one or more R_{10}.

12. The compound of any one of preceding claims, each R_7 is independently oxo, halogen, -OH, $-NH_2$, -CN, $-C(O)R_{10}$, C_{1-3} alkyl, C_{2-6} alkynyl, C_{1-6} alkoxy, $-O-(CH_2)_t-R_8$, C_{6-10} aryl, or 5- to 10-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, wherein the alkyl, alkynyl, aryl, or heteroaryl is substituted with one or more R_{10}.

13. The compound of any one of preceding claims, R_8 is -OH, C_{1-6} alkoxy, C_{1-6} alkoxy-OH, $-NH_2$, $-N(C_{1-6}$ alkyl$)_2$, $–S(C_{1-6}$ alkyl), 3- to 10-membered heterocyclyl comprising 1-4 heteroatoms selected from N, O, and S, or 5- to 10-membered heteroaryl comprising 1-4 heteroatoms selected

from N, O, and S, wherein the alkoxy, alkyl, heterocyclyl, or heteroaryl is optionally substituted by one or more R_9.

14. The compound of any one of preceding claims, R_8 is -OH, C_{1-6} alkoxy, C_{1-6} alkoxy-OH, -NH_2, -N(C_{1-6} alkyl)$_2$, –S(C_{1-6} alkyl), 3- to 10-membered heterocyclyl comprising 1-4 heteroatoms selected from N, O, and S, or 5- to 10-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, wherein the alkoxy, alkyl, heterocyclyl, or heteroaryl is substituted by one or more R_9.

15. The compound of any one of preceding claims, each R_9 is independently -$(CH_2)_u$-(5- to 10-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S) or -$(CH_2)_u$-(C_{6-10} aryl), wherein the heteroaryl or aryl is optionally substituted with one or more halogen or -OH.

16. The compound of any one of preceding claims, each R_9 is independently -$(CH_2)_u$-(5- to 10-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S) or -$(CH_2)_u$-(C_{6-10} aryl), wherein the heteroaryl or aryl is substituted with one or more halogen or -OH.

17. The compound of any one of preceding claims, each R_{10} is independently C_{1-6} alkyl, C_{1-6} haloalkyl, or 5- to 10-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S.

18. The compound of any one of preceding claims, each R_{11} is independently H, C_{1-6} alkyl optionally substituted with one or more 3- to 10-membered heterocyclyl comprising 1-4 heteroatoms selected from N, O, and S, C_{6-10} aryl, or 5- to 10-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, wherein the heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more 5- to 10-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, C_{1-6} alkyl, or oxo.

19. The compound of any one of preceding claims, each R_{11} is independently H, C_{1-6} alkyl optionally substituted with one or more 3- to 10-membered heterocyclyl comprising 1-4 heteroatoms selected from N, O, and S, C_{6-10} aryl, or 5- to 10-membered heteroaryl comprising

1-4 heteroatoms selected from N, O, and S, wherein the heterocyclyl, aryl, or heteroaryl is substituted with one or more 5- to 10-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, C_{1-6} alkyl, or oxo.

20. The compound of any one of preceding claims, each R_{11} is independently H, C_{1-6} alkyl substituted with one or more 3- to 10-membered heterocyclyl comprising 1-4 heteroatoms selected from N, O, and S, C_{6-10} aryl, or 5- to 10-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, wherein the heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more 5- to 10-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, C_{1-6} alkyl, or oxo.

21. The compound of any one of preceding claims, two R_{11} together with the atom to which they are attached form a 4- to 10-membered heterocyclyl comprising 1-4 heteroatoms selected from N, O, and S, optionally substituted with one or more C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, halogen, -CN, -OH, or $-NH_2$.

22. The compound of any one of preceding claims, two R_{11} together with the atom to which they are attached form a 4- to 10-membered heterocyclyl comprising 1-4 heteroatoms selected from N, O, and S, substituted with one or more C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, halogen, -CN, -OH, or $-NH_2$.

23. The compound of any one of preceding claims, each n is 0.

24. The compound of any one of preceding claims, each n is 1.



25. The compound of any one of preceding claims, each m is 0.

26. The compound of any one of preceding claims, each m is 1.


27. The compound of any one of preceding claims, each p is 0.

28. The compound of any one of preceding claims, each p is 1.


29. The compound of any one of preceding claims, wherein either R_2 or R_3 is not H.

30. The compound of any one of preceding claims, wherein when R_5 and R_6 together with the atoms to which they are attached form a heterocyclyl or heteroaryl, A is not  or  .

31. The compound of claim 1 or 2, wherein the compound is of Formula (I-a) or (I-b):




(I-a), or




(I-b)

or a pharmaceutically acceptable prodrug, solvate, enantiomer, stereoisomer, tautomer, or salt thereof.


32. The compound of claim 1 or 2, wherein the compound is of Formula (I-c), (I-d), or (I-e):



(I-c),




(I-d), or




(I-e)

or a pharmaceutically acceptable prodrug, solvate, enantiomer, stereoisomer, tautomer, or salt thereof.

33. The compound of claim 1 or 2, wherein the compound is of Formula (I-a') or (I-b'):




(I-a'), or



(I-b')

or a pharmaceutically acceptable prodrug, solvate, enantiomer, stereoisomer, tautomer, or salt thereof.


34. The compound of any one of claims 1-3, wherein the compound is of Formula (II-a):



(II-a)

or a pharmaceutically acceptable prodrug, solvate, enantiomer, stereoisomer, tautomer, or salt thereof.






35. The compound of any one of claims 1-3, wherein the compound is of Formula (II-a'):




















(II-a')








or a pharmaceutically acceptable prodrug, solvate, enantiomer, stereoisomer, tautomer, or salt thereof.








36. The compounds of any one of claims 1-3, wherein the compound is selected from any one of the following:~~from Table 1.~~







Cmpnd No.	Structure
1	
2	
3	
4	
5	







Cmpnd No.	Structure
6	
7	
8	
9	
10	
11	
12	
13	
14	






Cmpnd No.	Structure
15	
16	
17	
18	
19	
20	
21	
22	







Cmpnd No.	Structure
23	
24	
25	
26	
27	
28	
29	







Cmpnd No.	Structure
30	
31	
32	
33	
34	
35	
36	







Cmpnd No.	Structure
37	
38	
39	
40	
41	
42	







Cmpnd No.	Structure
43	
44	
45	
46	
47	
48	








Cmpnd No.	Structure
49	
50	
51	
52	
53	






Cmpnd No.	Structure
54	
55	
56	
57	
58	
59	






Cmpnd No.	Structure
60	
61	
62	
63	
64	
65	







Cmpnd No.	Structure
66	
67	
68	
69	
70	
71	







Cmpnd No.	Structure
72	
73	
74	
75	
76	
77	







Cmpnd No.	Structure
78	
79	
80	
81	
82	
83	
84	







Cmpnd No.	Structure
85	
86	
87	
88	
89	






Cmpnd No.	Structure
90	
91	
92	
93	
94	







Cmpnd No.	Structure
95	
96	
97	
98	
99	
100	







Cmpnd No.	Structure
101	
102	
103	
104	
105	
106	







Cmpnd No.	Structure
107	
108	
109	
110	
111	
112	







Cmpnd No.	Structure
113	
114	
115	
116	
117	
118	







Cmpnd No.	Structure
119	
120	
121	
122	
123	






Cmpnd No.	Structure
124	
125	
126	
127	
128	
129	






Cmpnd No.	Structure
130	
131	
132	
133	
134	
135	







Cmpnd No.	Structure
136	
137	
138	
139	
140	
141	






Cmpnd No.	Structure
142	
143	
144	
145	
146	
147	






Cmpnd No.	Structure
148	
149	
150	
151	
152	
153	






Cmpnd No.	Structure
154	
155	
156	
157	
158	






Cmpnd No.	Structure
159	
160	
161	
162	
163	






Cmpnd No.	Structure
164	
165	
166	
167	
168	
169	





Cmpnd No.	Structure
170	
171	
172	
173	
174	






Cmpnd No.	Structure
175	
176	
177	
178	
179	






Cmpnd No.	Structure
180	
181	
182	
183	
184	






Cmpnd No.	Structure
185	
186	
187	
188	
189	






Cmpnd No.	Structure
190	
191	
192	
193	
194	






Cmpnd No.	Structure
195	
196	
197	
198	






Cmpnd No.	Structure
199	
200	
201	
202	
203	






Cmpnd No.	Structure
204	
205	
206	
207	
208	







Cmpnd No.	Structure
209	
210	
211	
212	
213	





Cmpnd No.	Structure
214	
215	
216	
217	
218	





Cmpnd No.	Structure
219	
220	
221	
222	
223	






Cmpnd No.	Structure
224	
225	
226	
227	
228	






Cmpnd No.	Structure
229	
230	
231	
232	
233	






Cmpnd No.	Structure
234	
235	
236	
237	
238	
239	






Cmpnd No.	Structure
240	
241	
242	
243	







Cmpnd No.	Structure
244	
245	
246	
247	







Cmpnd No.	Structure
248	
249	
250	
251	
252	





Cmpnd No.	Structure
253	
254	
255	
256	
257	

Cmpnd No.	Structure
258	
259	
260	
261	
262	

Cmpnd No.	Structure
263	
264	
265	
266	
267	

Cmpnd No.	Structure
268	
269	
270	
271	
272	
273	

Cmpnd No.	Structure
274	
275	
276	
277	
278	
279	

Cmpnd No.	Structure
280	
281	
282	
283	

.

37. A pharmaceutical composition comprising a compound of any one of claims 1-36, or a pharmaceutically acceptable prodrug, solvate, enantiomer, stereoisomer, tautomer, or salt thereof, and a pharmaceutically acceptable diluent or carrier.

~~38. A method of modulating P-glycoprotein activity and/or cytochrome P450 activity, comprising contacting a cell with an effective amount of a compound of any one of claims 1-36 or a pharmaceutical composition of claim 37.~~

~~39. A method of treating or preventing a disease or disorder disclosed herein in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of any one of claims 1-36 or a pharmaceutical composition of claim 37.~~

~~40. A method of treating or preventing a cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of any one of claims 1-36 or a pharmaceutical composition of claim 37.~~

~~41~~38. A compound of any one of claims 1-36 or a pharmaceutical composition of claim 37, for use in modulating P-glycoprotein activity and/or cytochrome P450 activity.

~~42~~39. A compound of any one of claims 1-36 or a pharmaceutical composition of claim 37, for use in therapy~~treating or preventing a disease or disorder disclosed herein~~.

~~43~~40. A compound of any one of claims 1-36 or a pharmaceutical composition of claim 37, for use in treating or preventing a cancer.

~~44~~41. Use of a compound of any one of claims 1-36 or a pharmaceutical composition of claim 37, in the manufacture of a medicament for modulating P-glycoprotein activity and/or cytochrome P450 activity.

~~45. Use of a compound of any one of claims 1-36 or a pharmaceutical composition of claim 37, in the manufacture of a medicament for treating or preventing a disease or disorder disclosed herein.~~

~~46~~42. Use of a compound of any one of claims 1-36 or a pharmaceutical composition of claim 37, in the manufacture of a medicament for treating or preventing a cancer.